Janssen Pharmaceutical Cos. and Legend Biotech Corp. plan a phased launch of their newly approved autologous chimeric antigen receptor T-cell (CAR-T) multiple myeloma therapy Carvykti (ciltacabtagene autoleucel), which targets B-cell maturation antigen (BCMA) on myeloma cells, to make sure treatments centers are ready to properly administer the complex product.
Johnson & Johnson’s Janssen subsidiary and Legend will launch Carvykti at a list price of $465,000 for the one-time...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?